Is this the start of a comeback for Iovance Biotherapeutics (NASDAQ: IOVA)? Though the small-cap biotech has significantly trailed the broader market in the past five years, its shares are up by 50% since 2024 started. Iovance is making progress on several fronts (more on that below).

It's no wonder that many investors are increasingly excited about the company's direction. But should long-term investors put their hard-earned money into this stock today? Let's find out.

Continue reading

Source Fool.com